Close Menu

R&D, Ruh-Roh

Pharmaceutical companies are watching their R&D costs go up, up, up, as they search for the next blockbuster drug amid dried-up pipelines and upcoming patent cliffs, reports The Guardian's Julia Kollewe. A recent Deloitte report shows that the cost of bringing a drug to market for the world's 12 biggest pharma companies has risen by more than 25 percent to about $1 billion this year from about $830 million in 2010, Kollewe says.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

The Wall Street Journal reports on gaps in COVID-19 testing affecting less affluent urban areas and rural locations.

According to NBC News, new SARS-CoV-2 variants are making it harder for researchers to model the course of the pandemic.

The New York Times reports that experts say President Joe Biden's goal of vaccinating 1 million people a day in the US in the next 100 days is too low a bar.

In Science this week: single-cell lineage tracing technique applied to study lung cancer metastasis, and more.